These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27156131)

  • 1. Reply to Herney Andrés García-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82: Looking Deeper: P-hacking and Some Other Bias.
    Rider JR; Wilson KM; Sinnott JA; Kelly RS; Mucci LA; Giovannucci EL
    Eur Urol; 2016 Dec; 70(6):e156-e157. PubMed ID: 27156131
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82: Looking Deeper: P-hacking and Some Other Bias.
    García-Perdomo HA; Manzano Nunez R
    Eur Urol; 2016 Dec; 70(6):e155. PubMed ID: 27156130
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Cédric Annweiler, Pierre Bigot, and Spyridon N. Karras' Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82.
    Rider JR; Wilson KM; Mucci LA; Giovannucci EL
    Eur Urol; 2017 Jan; 71(1):e18. PubMed ID: 27317088
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82.
    Annweiler C; Bigot P; Karras SN
    Eur Urol; 2017 Jan; 71(1):e16-e17. PubMed ID: 27267886
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?
    Boevé LMS; Vis AN
    Eur Urol; 2019 Apr; 75(4):e101-e102. PubMed ID: 30503181
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Epstein JI; Trock B; Han M
    Eur Urol; 2017 Jul; 72(1):e11-e12. PubMed ID: 28108147
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory.
    Sathianathen NJ; Konety BR
    Eur Urol; 2019 Jul; 76(1):e10-e11. PubMed ID: 30665809
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
    Vickers AJ; Lilja H; Assel M
    Eur Urol; 2019 Mar; 75(3):e56. PubMed ID: 30327273
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Dr Ramiro Manzano Nunez's comments.
    Oshio T
    J Epidemiol Community Health; 2016 Jul; 70(7):737. PubMed ID: 26822878
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.
    Glicksman RM; Berlin A
    Eur Urol; 2021 Sep; 80(3):e79-e80. PubMed ID: 34158186
    [No Abstract]   [Full Text] [Related]  

  • 11. Ejaculation frequency and subsequent risk of prostate cancer.
    Leitzmann MF; Platz EA; Stampfer MJ; Willett WC; Giovannucci E
    JAMA; 2004 Apr; 291(13):1578-86. PubMed ID: 15069045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
    Gillessen S; de Bono JS; Sartor O; Omlin AG
    Eur Urol; 2018 Feb; 73(2):e32-e33. PubMed ID: 28869069
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Xiaoling Lin, Brian T. Helfand, and Jianfeng Xu's Letter to the Editor re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol 2019;76:329-37.
    Kote-Jarai Z; Leongamornlert DA; Saunders EJ; Conti DV; Eeles RA
    Eur Urol; 2019 Nov; 76(5):e130-e131. PubMed ID: 31235193
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
    Bayne CE; Williams -B; Chapin BF
    Eur Urol; 2017 Feb; 71(2):e51. PubMed ID: 27461403
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Zietman A; Smith J; Klein E; Droller M; Dasgupta P; Catto J
    Eur Urol; 2017 Feb; 71(2):e54. PubMed ID: 27452952
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Julia Klap and Kevin R. Loughlin's letter to the editor re: Mohit Khera, David Crawford, Alvaro Morales, Andrea Salonia, Abraham Morgentaler. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115-23.
    Khera M; Morgentaler A
    Eur Urol; 2014 Aug; 66(2):e33. PubMed ID: 24836155
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942-9. The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer.
    Klein EA
    Eur Urol; 2017 Dec; 72(6):e174. PubMed ID: 28789805
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Pär Stattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56-61.
    Klil-Drori AJ; Azoulay L
    Eur Urol; 2017 Feb; 71(2):e63. PubMed ID: 27567205
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Sivaraman A; Barret E
    Eur Urol; 2017 May; 71(5):e148-e149. PubMed ID: 28161029
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6. Prebiopsy MRI: Through the Looking Glass.
    Vickers A; Carlsson SV; Cooperberg M
    Eur Urol; 2020 Sep; 78(3):314-315. PubMed ID: 32631742
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.